Q3 Earnings Forecast for ASND Issued By HC Wainwright

Ascendis Pharma A/S (NASDAQ:ASND) – Analysts at HC Wainwright issued their Q3 2026 EPS estimates for Ascendis Pharma A/S in a report released on Thursday, August 27th. HC Wainwright analyst M. Kapoor forecasts that the biotechnology company will post earnings of $1.16 per share for the quarter. HC Wainwright has a “Buy” rating and a $345.00 price target on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is $3.90 per share. HC Wainwright also issued estimates for Ascendis Pharma A/S’s Q4 2026 earnings at $1.66 EPS, FY2026 earnings at $3.93 EPS, Q1 2027 earnings at $1.76 EPS, Q2 2027 earnings at $2.48 EPS, Q3 2027 earnings at $3.20 EPS, Q4 2027 earnings at $4.42 EPS and FY2027 earnings at $11.88 EPS.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The firm had revenue of $387.22 million during the quarter, compared to analysts’ expectations of $376.75 million.

A number of other analysts have also commented on ASND. Oppenheimer reiterated an “outperform” rating and set a $312.00 price target on shares of Ascendis Pharma A/S in a report on Tuesday. Evercore restated an “outperform” rating and issued a $329.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Wedbush reaffirmed an “outperform” rating and set a $327.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday. Wells Fargo & Company lowered their target price on Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Finally, Citigroup initiated coverage on shares of Ascendis Pharma A/S in a research report on Monday, May 18th. They set a “buy” rating and a $355.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Ascendis Pharma A/S has an average rating of “Buy” and an average target price of $310.05.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ ASND opened at $260.25 on Monday. The company has a market capitalization of $16.23 billion, a PE ratio of 20.19 and a beta of 0.35. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. The stock’s 50 day moving average price is $256.87 and its 200-day moving average price is $239.75. Ascendis Pharma A/S has a twelve month low of $186.05 and a twelve month high of $282.15.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP raised its stake in Ascendis Pharma A/S by 95.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock valued at $357,645,000 after acquiring an additional 880,836 shares during the period. Perceptive Advisors LLC boosted its position in Ascendis Pharma A/S by 41.6% during the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock worth $350,282,000 after purchasing an additional 450,000 shares during the period. Principal Financial Group Inc. increased its stake in shares of Ascendis Pharma A/S by 29.3% in the fourth quarter. Principal Financial Group Inc. now owns 1,026,407 shares of the biotechnology company’s stock worth $218,871,000 after purchasing an additional 232,730 shares in the last quarter. Vestal Point Capital LP increased its stake in shares of Ascendis Pharma A/S by 200.0% in the third quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company’s stock worth $119,286,000 after purchasing an additional 400,000 shares in the last quarter. Finally, FIL Ltd raised its position in shares of Ascendis Pharma A/S by 4.2% in the fourth quarter. FIL Ltd now owns 478,641 shares of the biotechnology company’s stock valued at $102,065,000 after purchasing an additional 19,301 shares during the period.

Insiders Place Their Bets

In other news, Director Jean Jacques Bienaime bought 2,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was acquired at an average cost of $246.33 per share, with a total value of $492,660.00. Following the completion of the transaction, the director directly owned 2,900 shares of the company’s stock, valued at $714,357. This represents a 222.22% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 40.00% of the company’s stock.

Trending Headlines about Ascendis Pharma A/S

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: BioMarin settlement removes litigation overhang: Ascendis and BioMarin entered a binding term sheet for a global settlement and license agreement covering YUVIWEL® and navepegritide-related products. The agreement is intended to resolve all litigation and disputes between the companies, reducing legal uncertainty around the product. Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL Shares increased following news of the license deal. Ascendis Pharma Shares Rise 6% Over License Deal With BioMarin Pharmaceutical
• Positive Sentiment: Wedbush remains bullish: Wedbush reaffirmed its “Outperform” rating and set a $327 price target, implying substantial upside from the referenced share price. The rating signals continued confidence in Ascendis’ growth prospects and product pipeline. Wedbush Reaffirms Ascendis Pharma Outperform Rating
• Neutral Sentiment: Analyst consensus remains favorable: Ascendis Pharma received an average analyst rating of “Buy,” indicating that Wall Street sentiment remains broadly positive despite recent estimate revisions. Ascendis Pharma Receives Average Rating of Buy from Analysts
• Negative Sentiment: HC Wainwright cuts forward EPS forecasts: The firm reduced its estimates for the third and fourth quarters of 2026, all four quarters of 2027, and FY2027 EPS to $11.25 from $11.88. Although HC Wainwright maintained its “Buy” rating and $345 price target, the lower forecasts suggest a more cautious outlook for near-term earnings growth.
• Negative Sentiment: Bank of America trims its target: Bank of America lowered its price objective to $304 from $306 while retaining a “Buy” rating, representing a modest reduction in expected upside.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.